The information contained on the following web pages is intended exclusively for

Swiss residents who are physically located in Switzerland; or
persons who are located or resident in a member state of the EEA and are a “qualified investor” within the meaning of Article 2(1)(e) of the Prospectus Regulation; or
persons who are located or resident in the UK who are not a “retail client” as set out in the Markets in Financial Instruments Directive 2014/65/EU and qualify as (a) investment professionals falling within Article 19(5) of the Order, (b) high net worth entities falling within Article 49(2)(a) to (d) of the Order, or (c) other persons to whom it may lawfully be communicated, all such persons under (a) to (c) together being referred to as “relevant persons; or
persons who qualify as a “qualified institutional buyer” (as defined in Rule 144A under the U.S. Securities Act).

The following information does not contain or constitute an offer to sell or a solicitation of any offer to buy securities in the United States of America (“U.S.“) or in any other jurisdiction in which such offer or solicitation is not authorized or to any person to whom it is unlawful to make an offer or solicitation. Users of this web site are requested to inform themselves about and to observe any such restrictions. The securities in Cosmo Pharmaceuticals N.V. have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “U.S. Securities Act”), or under any law of any state of the United States of America, and may not be offered, sold, resold, or delivered, directly or indirectly, in or into the U.S., except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. The website and the investment activity to which it relates does not constitute an offer to sell or the solicitation of an offer to buy any securities in the U.S. or in any other jurisdiction in which such an offer or solicitation would be unlawful. Cosmo Pharmaceuticals N.V. will not register or make a public offer of its securities, or otherwise conduct any public tender offer, in the U.S. In the United States, this website is solely directed towards “qualified institutional buyers” (as defined in Rule 144A under the U.S. Securities Act) on a confidential basis. Neither the United States Securities and Exchange Commission nor any state securities commission in the United States has approved or disapproved the Offering of the shares or passed upon the adequacy or accuracy of the Prospectus. Any representation to the contrary is a criminal offence in the United States. PROSPECTIVE PURCHASERS ARE HEREBY NOTIFIED THAT SELLERS OF SHARES IN COSMO PHARMACEUTICALS N.V. MAY BE RELYING ON THE EXEMPTION FROM THE PROVISIONS OF SECTION 5 OF THE US SECURITIES ACT PROVIDED BY RULE 144A.

This website and the investment activity to which it relates is furthermore solely directed towards persons who do not fall within the definition of a “retail client” set out in the Markets in Financial Instruments Directive 2014/65/EU, and to whom this document may otherwise be lawfully distributed without the requirement to provide a Key Investor Information Document in accordance with the Packaged Retail and Insurance-based Investment Products Regulation (EU) No 1286/2014.

In particular, but without prejudice to the generality of the foregoing, this website and the investment activity to which it relates may only be communicated to, and is only directed at persons within the United Kingdom:

having professional experience in matters relating to investments, being investment professionals as defined in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (as amended) (“FPO“);
falling within Article 49(2)(a) to (d) of the FPO (including high net worth companies and unincorporated associations); or
to whom the communication may otherwise lawfully be made.

Some of the information published on this website contains forward-looking statements. Users are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo Pharmaceuticals N.V. does not undertake any obligation to publicly update or revise any information or opinions published on the website and reserves the right to amend the information at any time without prior notice.

The information contained on this website may not be considered as being a substitute for economic, legal, tax or other advice and users are cautioned to base investment decisions or other decisions solely on the content of this website. An investment decision with respect to securities of Cosmo Pharmaceuticals N.V. must only be made on the basis of the offering prospectus published by Cosmo Pharmaceuticals N.V. for that purpose in accordance with Swiss law. Users must consult their investment advisers or other advisers prior to making any decisions.

Confirmation of understanding and acceptance of disclaimer

By clicking on the “I AGREE” button, I certify that:

I am located in Switzerland and I am physically present in Switzerland; or
I am located in the EEA and I am a “qualified investor” (as defined above); and, if located in the UK, and I am a “Relevant Person” (as defined above); or
I am located in the US and I am a “qualified institutional buyer” (as defined in Rule 144A under the U.S. Securities Act) “.

I have read and understood the disclaimer set out above. I understand that it may affect my rights. I agree to be bound by its terms. By clicking on the “I AGREE” button, I confirm that I am permitted to proceed to electronic versions of these materials.

Disclaimer

Share price

Helpful links